Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating’
Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...
Hims & Hers price target raised to $27 from $23 at Deutsche Bank
Deutsche Bank analyst George Hill raised the firm’s price target on Hims & Hers to $27 from $23 and keeps a Hold rating on the shares ...
Hims & Hers Health, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Hims & Hers Health, Inc. investors will be delighted, with the company turning in some strong numbers with its latest results. It was overall a positive result, with revenues beat ...
Seeking Alpha1d
Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong ...
Hims & Hers stock could dive soon despite strong results
Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...
Business Insider1d
Hims & Hers Health (HIMS) Gets a Hold from Truist Financial
Truist Financial analyst Jailendra Singh maintained a Hold rating on Hims & Hers Health (HIMS – Research Report) today. The company’s shares closed yesterday at $20.76. According to TipRanks, ...
Hims & Hers Health: Another Blowout Quarter Ignored
Hims & Hers Health exceeded revenue expectations, achieved substantial subscriber growth, and remains undervalued in the ...
Hims & Hers Health Reports Better-Than-Expected Q3 Results: Details
Hims & Hers Health reported its third-quarter results after Monday's closing bell. Here's a look at the details from the ...
Stocktwits on MSN1d
Hims & Hers Soars Pre-Market After Analysts Boost Price Targets On Strong Q3 Performance
Hims & Hers Health Inc. ($HIMS) rallied nearly 9% in pre-market trading on Tuesday, following the company’s third-quarter ...